

David Goldstein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/546740/publications.pdf>

Version: 2024-02-01

280
papers

17,544
citations

28274
55
h-index

15266
126
g-index

285
all docs

285
docs citations

285
times ranked

19943
citing authors

#	ARTICLE	IF	CITATIONS
1	Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review. <i>Journal of Cancer Survivorship</i> , 2023, 17, 222-236.	2.9	20
2	Effectively communicating comprehensive tumor genomic profiling results: Mitigating uncertainty for advanced cancer patients. <i>Patient Education and Counseling</i> , 2022, 105, 452-459.	2.2	5
3	Value of whole-genome sequencing to Australian cancer patients and their first-degree relatives participating in a genomic sequencing study. <i>Journal of Genetic Counseling</i> , 2022, 31, 96-108.	1.6	2
4	Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 39-51.	2.4	0
5	Psychological predictors of advanced cancer patients' preferences for return of results from comprehensive tumor genomic profiling. <i>American Journal of Medical Genetics, Part A</i> , 2022, 188, 725-734.	1.2	2
6	Clinical and molecular profile of young adults with early-onset colorectal cancer: Experience from four Australian tertiary centers. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, , .	1.1	1
7	Psychological impact of comprehensive tumor genomic profiling results for advanced cancer patients. <i>Patient Education and Counseling</i> , 2022, 105, 2206-2216.	2.2	4
8	INTEGRATE IIb: A randomized phase III open label study of regorafenib + nivolumab versus standard chemotherapy in refractory advanced gastroesophageal cancer (AGOC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS366-TPS366.	1.6	2
9	The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours. <i>Targeted Oncology</i> , 2022, 17, 95.	3.6	2
10	Development and consensus process for a clinical pathway for the assessment and management of chemotherapy-induced peripheral neuropathy. <i>Supportive Care in Cancer</i> , 2022, 30, 5965-5974.	2.2	2
11	Psychological outcomes in advanced cancer patients after receiving genomic tumor profiling results.. <i>Health Psychology</i> , 2022, 41, 396-408.	1.6	1
12	Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use. <i>Quality of Life Research</i> , 2022, 31, 3091-3107.	3.1	11
13	Molecular therapy selection in treatment-refractory advanced cancers: A retrospective cohort study determining the utility of TOPOGRAPH knowledge base.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3073-3073.	1.6	0
14	Two years of the Australian Rare Cancer Portal: a national referral service for rare cancer information and research.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18581-e18581.	1.6	0
15	The psychosocial impact of the Australian Rare Cancer Portal on patients with rare cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e24127-e24127.	1.6	0
16	Return of comprehensive tumour genomic profiling results to advanced cancer patients: a qualitative study. <i>Supportive Care in Cancer</i> , 2022, 30, 8201-8210.	2.2	1
17	Family communication about genomic sequencing: A qualitative study with cancer patients and relatives. <i>Patient Education and Counseling</i> , 2021, 104, 944-952.	2.2	11
18	Circulating tumour cells in pancreatic cancer: A systematic review and meta-analysis of clinicopathological implications. <i>Pancreatology</i> , 2021, 21, 103-114.	1.1	11

#	ARTICLE	IF	CITATIONS
19	Ex vivo culture of intact human patient derived pancreatic tumour tissue. Scientific Reports, 2021, 11, 1944.	3.3	27
20	Destructive soft tissue metastases in advanced colorectal cancer: a case report. Annals of Palliative Medicine, 2021, .	1.2	0
21	Genetic associations of fatigue and other symptoms following breast cancer treatment: A prospective study. Brain, Behavior, & Immunity - Health, 2021, 10, 100189.	2.5	9
22	Challenges and solutions to sharing a cancer follow-up e-care plan between a cancer service and general practice. Public Health Research and Practice, 2021, 31, .	1.5	5
23	Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy. JAMA Network Open, 2021, 4, e2036695.	5.9	49
24	Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)ât. Annals of Oncology, 2021, 32, 533-541.	1.2	34
25	Clinical assessment of chemotherapy-induced peripheral neuropathy: a discrete choice experiment of patient preferences. Supportive Care in Cancer, 2021, 29, 6379-6387.	2.2	4
26	Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition. Cancer Research, 2021, 81, 3461-3479.	0.9	62
27	Does the Microenvironment Hold the Hidden Key for Functional Precision Medicine in Pancreatic Cancer?. Cancers, 2021, 13, 2427.	3.7	6
28	Australasian Gastro-Intestinal Trials Group (AGITG) MASTERPLAN: Randomized phase II study of modified neoadjuvant FOLFIRINOX alone or in combination with stereotactic radiotherapy (SBRT) for patients with high-risk and locally advanced pancreatic cancer.. Journal of Clinical Oncology, 2021, 39, TPS4172-TPS4172.	1.6	1
29	HGF/c-Met Inhibition as Adjuvant Therapy Improves Outcomes in an Orthotopic Mouse Model of Pancreatic Cancer. Cancers, 2021, 13, 2763.	3.7	7
30	Longitudinal patterns in fear of cancer progression in patients with rare, advanced cancers undergoing comprehensive tumour genomic profiling. Psycho-Oncology, 2021, 30, 1920-1929.	2.3	0
31	Corneal nerve changes following treatment with neurotoxic anticancer drugs. Ocular Surface, 2021, 21, 221-237.	4.4	7
32	Chemotherapy-Induced Peripheral Neurotoxicity in Cancer Survivors: Predictors of Long-Term Patient Outcomes. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 821-828.	4.9	24
33	Investigation of Relation of Radiation Therapy Quality With Toxicity and Survival in LAP07 Phase 3 Trial for Locally Advanced Pancreatic Carcinoma. International Journal of Radiation Oncology Biology Physics, 2021, 110, 993-1002.	0.8	6
34	AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer. BMC Cancer, 2021, 21, 936.	2.6	12
35	Evidence of slow and variable choice-stepping reaction time in cancer survivors with chemotherapy-induced peripheral neuropathy. Gait and Posture, 2021, 89, 178-185.	1.4	2
36	Gender representation in authorship in later-phase systemic clinical trials in biliary tract cancer (BTC).. Journal of Clinical Oncology, 2021, 39, 348-348.	1.6	0

#	ARTICLE	IF	CITATIONS
37	The effect of exercise intensity on exercise-induced hypoalgesia in cancer survivors: A randomized crossover trial. <i>Physiological Reports</i> , 2021, 9, e15047.	1.7	2
38	hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. <i>Cancers</i> , 2021, 13, 5758.	3.7	5
39	Corneal dendritic cells and the subbasal nerve plexus following neurotoxic treatment with oxaliplatin or paclitaxel. <i>Scientific Reports</i> , 2021, 11, 22884.	3.3	11
40	Quantification of Small Fiber Neuropathy in Chemotherapy-Treated Patients. <i>Journal of Pain</i> , 2020, 21, 44-58.	1.4	22
41	The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy. <i>Acta Oncologica</i> , 2020, 59, 20-27.	1.8	3
42	Targeting the undruggable in pancreatic cancer using nano-based gene silencing drugs. <i>Biomaterials</i> , 2020, 240, 119742.	11.4	46
43	Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiation Therapy (SBRT). <i>Practical Radiation Oncology</i> , 2020, 10, e136-e146.	2.1	41
44	Advanced cancer patient preferences for receiving molecular profiling results. <i>Psycho-Oncology</i> , 2020, 29, 1533-1539.	2.3	5
45	Targeting HGF/c-MET Axis in Pancreatic Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9170.	4.1	35
46	Determining the CA19-9 concentration that best predicts the presence of CT-occult unresectable features in patients with pancreatic cancer: A population-based analysis. <i>Pancreatology</i> , 2020, 20, 1458-1464.	1.1	5
47	Reply letter to comments on: Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis. <i>British Journal of Cancer</i> , 2020, 123, 1466-1466.	6.4	1
48	Assessment of the Value of Tumor Variation Profiling Perceived by Patients With Cancer. <i>JAMA Network Open</i> , 2020, 3, e204721.	5.9	7
49	Oxaliplatin-induced haematological toxicity and splenomegaly in mice. <i>PLoS ONE</i> , 2020, 15, e0238164.	2.5	12
50	Acute changes in nerve excitability following oxaliplatin treatment in mice. <i>Journal of Neurophysiology</i> , 2020, 124, 232-244.	1.8	9
51	Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis. <i>British Journal of Cancer</i> , 2020, 122, 1486-1495.	6.4	45
52	Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib. <i>JAMA Surgery</i> , 2020, 155, e200397.	4.3	29
53	Impact of migrancy on cancer clinical trial participation: Factors associated with approach and consent in Australian-born versus migrant groups. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 115-122.	1.1	2
54	Self-reported health, lifestyle and social circumstances of Australian adult cancer survivors: A propensity score weighted cross-sectional study. <i>Cancer Epidemiology</i> , 2020, 67, 101773.	1.9	2

#	ARTICLE	IF	CITATIONS
55	The AGITG GAP Study: A Phase II Study of Perioperative Gemcitabine and Nab-Paclitaxel for Resectable Pancreas Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 2506-2515.	1.5	18
56	The impact of anticancer drugs on the ocular surface. <i>Ocular Surface</i> , 2020, 18, 403-417.	4.4	13
57	Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. <i>Journal of Hepatology</i> , 2020, 73, 1109-1117.	3.7	25
58	Phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) versus gemcitabine (Gem) alone for patients with resected pancreatic cancer (PC): Outcomes by geographic region.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4515-4515.	1.6	11
59	Concordance between independent and investigator assessment of disease-free survival (DFS) in the APACT trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4618-4618.	1.6	1
60	The synergistic inhibitory effect of combining therapies targeting EGFR and mitochondria in sarcomas. <i>Oncotarget</i> , 2020, 11, 46-61.	1.8	1
61	An Orthotopic Resectional Mouse Model of Pancreatic Cancer. <i>Journal of Visualized Experiments</i> , 2020, , .	0.3	3
62	Return of results after somatic tumor mutation profiling in advanced cancer: Psychological impacts.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1541-1541.	1.6	0
63	Determining the impact of chemotherapy-induced peripheral neuropathy: A survey of cancer survivors.. <i>Journal of Clinical Oncology</i> , 2020, 38, e24080-e24080.	1.6	0
64	Barriers and enablers to the implementation of protocol-based imaging in pancreatic cancer: A qualitative study using the theoretical domains framework. <i>PLoS ONE</i> , 2020, 15, e0243312.	2.5	2
65	Optimizing Clinical Screening for Chemotherapy-Induced Peripheral Neuropathy. <i>Journal of Pain and Symptom Management</i> , 2019, 58, 1023-1032.	1.2	21
66	Patient perspectives on molecular tumor profiling: “Why wouldn’t you?” <i>BMC Cancer</i> , 2019, 19, 753.	2.6	21
67	Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. <i>Annals of Oncology</i> , 2019, 30, 1472-1478.	1.2	141
68	Mobility in survivors with chemotherapy-induced peripheral neuropathy and utility of the 6-min walk test. <i>Journal of Cancer Survivorship</i> , 2019, 13, 495-502.	2.9	14
69	Chemotherapy-induced peripheral neuropathy—patient-reported outcomes compared with NCI-CTCAE grade. <i>Supportive Care in Cancer</i> , 2019, 27, 4771-4777.	2.2	30
70	Challenges and perceived unmet needs of Chinese migrants affected by cancer: Focus group findings. <i>Journal of Psychosocial Oncology</i> , 2019, 37, 383-397.	1.2	11
71	CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabine. <i>Future Oncology</i> , 2019, 15, 1295-1302.	2.4	37
72	Exercise-based rehabilitation for cancer survivors with chemotherapy-induced peripheral neuropathy. <i>Supportive Care in Cancer</i> , 2019, 27, 3849-3857.	2.2	56

#	ARTICLE	IF	CITATIONS
73	Accuracy and Prognostic Significance of Oncologists's Estimates and Scenarios for Survival Time in Advanced Gastric Cancer. <i>Oncologist</i> , 2019, 24, e1102-e1107.	3.7	9
74	Evaluation of Phase II Trial Design in Advanced Pancreatic Cancer. <i>Pancreas</i> , 2019, 48, 1274-1284.	1.1	2
75	Dorsal root ganglion explants derived from chemotherapy-treated mice have reduced neurite outgrowth in culture. <i>Neuroscience Letters</i> , 2019, 694, 14-19.	2.1	23
76	Monitoring quality of care for patients with pancreatic cancer: a modified Delphi consensus. <i>Hpb</i> , 2019, 21, 444-455.	0.3	20
77	Multimodality treatment of oligometastatic anal squamous cell carcinoma: A case series and literature review. <i>Journal of Surgical Oncology</i> , 2019, 119, 489-496.	1.7	14
78	Evaluation of an online communication skills training programme for oncology nurses working with patients from minority backgrounds. <i>Supportive Care in Cancer</i> , 2019, 27, 1951-1960.	2.2	12
79	The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2019, 269, 520-529.	4.2	189
80	Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. <i>Gut</i> , 2019, 68, 663-671.	12.1	234
81	APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4000-4000.	1.6	125
82	NUC-1031 in combination with cisplatin for first-line treatment of advanced biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS4156-TPS4156.	1.6	3
83	Balance Deficits and Functional Disability in Cancer Survivors Exposed to Neurotoxic Cancer Treatments. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 949-955.	4.9	27
84	Medical oncologists' experience with returning molecular tumor profiling to patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10521-10521.	1.6	1
85	Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. <i>British Journal of Cancer</i> , 2018, 118, 947-954.	6.4	30
86	Radiotherapy for anal squamous cell carcinoma: must the upper pelvic nodes and the inguinal nodes be treated?. <i>ANZ Journal of Surgery</i> , 2018, 88, 870-875.	0.7	5
87	Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. <i>Lancet Oncology</i> , The, 2018, 19, e151-e160.	10.7	51
88	Chemotherapy in patients with unresected pancreatic cancer in Australia: A population-based study of uptake and survival. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 326-336.	1.1	15
89	The PiGeOn project: protocol for a longitudinal study examining psychosocial, behavioural and ethical issues and outcomes in cancer tumour genomic profiling. <i>BMC Cancer</i> , 2018, 18, 389.	2.6	10
90	The PiGeOn project: protocol of a longitudinal study examining psychosocial and ethical issues and outcomes in germline genomic sequencing for cancer. <i>BMC Cancer</i> , 2018, 18, 454.	2.6	14

#	ARTICLE	IF	CITATIONS
91	A double blind, placebo controlled, phase II randomised cross-over trial investigating the use of duloxetine for the treatment of chemotherapy-induced peripheral neuropathy. Contemporary Clinical Trials, 2018, 70, 135-138.	1.8	9
92	Intratumoural expression of deoxycytidylate deaminase or ribonucleotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. British Journal of Cancer, 2018, 118, 1084-1088.	6.4	9
93	Multimodal quantitative examination of nerve function in colorectal cancer patients prior to chemotherapy. Muscle and Nerve, 2018, 57, 615-621.	2.2	2
94	Association between pancreatic cancer patients' perception of their care coordination and patient-reported and survival outcomes. Palliative and Supportive Care, 2018, 16, 534-543.	1.0	16
95	Oxaliplatin induces muscle loss and muscle-specific molecular changes in Mice. Muscle and Nerve, 2018, 57, 650-658.	2.2	22
96	Barriers and facilitators of exercise experienced by cancer survivors: a mixed methods systematic review. Supportive Care in Cancer, 2018, 26, 685-700.	2.2	172
97	Biliary Stenting in Patients With Pancreatic Cancer. Pancreas, 2018, 47, 80-86.	1.1	7
98	Antitumour effects and mechanisms of action of the panHER inhibitor, dacomitinib, alone and in combination with the STAT3 inhibitor, S3I-201, in human sarcoma cell lines. International Journal of Oncology, 2018, 52, 2143-2154.	3.3	6
99	Performance status dynamics during treatment with &em>nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer. Cancer Management and Research, 2018, Volume 10, 1389-1396.	1.9	4
100	Patients's™ preferences for 3 months versus 6 months of adjuvant chemotherapy (ACT) for colon cancer in the SCOT trial: what survival benefits make longer chemotherapy worthwhile?. Journal of Clinical Oncology, 2018, 36, 3602-3602.	1.6	3
101	Circulating tumor DNA as a prognostic biomarker in early stage pancreatic cancer.. Journal of Clinical Oncology, 2018, 36, e16206-e16206.	1.6	4
102	Anxiety, depression and quality of life in people with pancreatic cancer and their carers. Pancreatology, 2017, 17, 321-327.	1.1	71
103	Systemic treatment in advanced biliary cancers: A multicenter Australian analysis and review. Asia-Pacific Journal of Clinical Oncology, 2017, 13, e291-e297.	1.1	3
104	Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy. European Journal of Cancer, 2017, 73, 22-29.	2.8	130
105	Randomized Evaluation of Cognitive-Behavioral Therapy and Graded Exercise Therapy for Post-Cancer Fatigue. Journal of Pain and Symptom Management, 2017, 54, 74-84.	1.2	45
106	Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer. Clinical Neurophysiology, 2017, 128, 1166-1175.	1.5	50
107	Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. Supportive Care in Cancer, 2017, 25, 3485-3493.	2.2	59
108	Circulating pancreatic stellate (stromal) cells in pancreatic cancer—a fertile area for novel research. Carcinogenesis, 2017, 38, 588-591.	2.8	19

#	ARTICLE	IF	CITATIONS
109	Communicating with patients from minority backgrounds: Individual challenges experienced by oncology health professionals. <i>European Journal of Oncology Nursing</i> , 2017, 26, 83-90.	2.1	27
110	Information needs of the Chinese community affected by cancer: A systematic review. <i>Psycho-Oncology</i> , 2017, 26, 1433-1443.	2.3	33
111	Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 951-964.	2.4	2
112	New molecular and immunotherapeutic approaches in biliary cancer. <i>ESMO Open</i> , 2017, 2, e000152.	4.5	26
113	Communication challenges experienced by migrants with cancer: A comparison of migrant and English-speaking Australian-born cancer patients. <i>Health Expectations</i> , 2017, 20, 886-895.	2.6	40
114	Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine. <i>Pancreas</i> , 2017, 46, 203-208.	1.1	24
115	Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials. <i>BMC Cancer</i> , 2017, 17, 262.	2.6	16
116	Rituximab to treat gemcitabine-induced hemolytic-uremic syndrome (HUS) in pancreatic adenocarcinoma: a case series and literature review. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 1-7.	2.3	15
117	Significance of Phosphorylated Epidermal Growth Factor Receptor and Its Signal Transducers in Human Soft Tissue Sarcoma. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1159.	4.1	15
118	Characterisation of Immune and Neuroinflammatory Changes Associated with Chemotherapy-Induced Peripheral Neuropathy. <i>PLoS ONE</i> , 2017, 12, e0170814.	2.5	177
119	The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0172307.	2.5	11
120	The role of chemotherapy in gastric cancer-related microangiopathic haemolytic anaemia. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, E10-E15.	1.4	3
121	The potential of circulating tumor DNA (ctDNA) to guide adjuvant chemotherapy decision making in locally advanced rectal cancer (LARC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3521-3521.	1.6	11
122	Potential role of circulating tumor DNA (ctDNA) in the early diagnosis and post-operative management of localised pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4101-4101.	1.6	9
123	Nomogram for predicting overall survival (OS) in patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) or Gem alone for metastatic pancreatic cancer (MPC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4109-4109.	1.6	4
124	Neutrophil count and efficacy of chemoradiation in patients with locally advanced unresectable pancreatic carcinoma: An ancillary study of in the LAP 07 trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4120-4120.	1.6	3
125	Integrate II: A randomised phase 3 double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer (AGOC) – An international study organized by the Australasian Gastrointestinal Trials Group (AGITG).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS4136-TPS4136.	1.6	9
126	Correlation of phase 2 trials (Ph2t) results with outcomes of phase 3 trials (Ph3t) of investigational agents (IA) in locally advanced and metastatic pancreas cancer (LAMPC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 227-227.	1.6	1

#	ARTICLE	IF	CITATIONS
127	MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity. <i>Oncotarget</i> , 2017, 8, 9216-9229.	1.8	13
128	Targeting the HGF/c-MET pathway: stromal remodelling in pancreatic cancer. <i>Oncotarget</i> , 2017, 8, 76722-76739.	1.8	70
129	Refining the care of patients with pancreatic cancer: the AGITG Pancreatic Cancer Workshop consensus. <i>Medical Journal of Australia</i> , 2016, 204, 419-422.	1.7	14
130	Factors associated with quality of care for patients with pancreatic cancer in Australia. <i>Medical Journal of Australia</i> , 2016, 205, 459-465.	1.7	20
131	Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 469-478.	1.4	48
132	Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 5461-5473.	2.0	41
133	A tsunami of unmet needs: pancreatic and ampullary cancer patients' supportive care needs and use of community and allied health services. <i>Psycho-Oncology</i> , 2016, 25, 150-157.	2.3	53
134	Determinants of survival and attempted resection in patients with non-metastatic pancreatic cancer: An Australian population-based study. <i>Pancreatology</i> , 2016, 16, 873-881.	1.1	14
135	Delineating the Role of β -Tubulins in Pancreatic Cancer: β -Tubulin Inhibition Sensitizes Pancreatic Cancer Cells to Vinca Alkaloids. <i>Neoplasia</i> , 2016, 18, 753-764.	5.3	18
136	Determinants of Outcomes Following Resection for Pancreatic Cancer—a Population-Based Study. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 1471-1481.	1.7	24
137	Inflammatory Markers Have a Role in Renal Cell Carcinoma Prognosis. <i>European Urology Focus</i> , 2016, 2, 341-342.	3.1	6
138	The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study. <i>Oncologist</i> , 2016, 21, 618-625.	3.7	12
139	Risk factors for current and future unmet supportive care needs of people with pancreatic cancer. A longitudinal study. <i>Supportive Care in Cancer</i> , 2016, 24, 3589-3599.	2.2	22
140	Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT). <i>European Journal of Cancer</i> , 2016, 52, 85-91.	2.8	36
141	Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1844.	7.4	801
142	Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. <i>British Journal of Cancer</i> , 2016, 115, 188-194.	6.4	76
143	Radiation Therapy Deviations in Trial of Locally Advanced Pancreatic Cancer—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1409.	7.4	0
144	Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP). <i>British Journal of Cancer</i> , 2016, 115, 281-289.	6.4	61

#	ARTICLE	IF	CITATIONS
145	Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3. <i>Pancreatology</i> , 2016, 16, 1106-1112.	1.1	13
146	Using a Delphi process to determine optimal care for patients with pancreatic cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 105-114.	1.1	9
147	TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 361-367.	2.3	15
148	Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 2728-2735.	1.6	183
149	A Rationally Optimized Nanoparticle System for the Delivery of RNA Interference Therapeutics into Pancreatic Tumors in Vivo. <i>Biomacromolecules</i> , 2016, 17, 2337-2351.	5.4	68
150	It's all good on the surface: care coordination experiences of migrant cancer patients in Australia. <i>Supportive Care in Cancer</i> , 2016, 24, 2403-2410.	2.2	16
151	Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?. <i>European Journal of Cancer</i> , 2016, 53, 96-104.	2.8	23
152	Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer. <i>British Journal of Cancer</i> , 2016, 114, 269-280.	6.4	81
153	CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. <i>Annals of Oncology</i> , 2016, 27, 654-660.	1.2	87
154	Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas. <i>Annals of Oncology</i> , 2016, 27, 648-653.	1.2	36
155	The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04). <i>European Journal of Cancer</i> , 2016, 55, 15-26.	2.8	45
156	Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. <i>BMC Cancer</i> , 2016, 16, 22.	2.6	52
157	Key role of pancreatic stellate cells in pancreatic cancer. <i>Cancer Letters</i> , 2016, 381, 194-200.	7.2	103
158	œl might not have cancer if you didn't mention it: a qualitative study on information needed by culturally diverse cancer survivors. <i>Supportive Care in Cancer</i> , 2016, 24, 409-418.	2.2	27
159	Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. <i>Annals of Oncology</i> , 2016, 27, 134-140.	1.2	88
160	Initial survival outcomes for the AGITG GAP study œ a phase II study of perioperative nab-paclitaxel and gemcitabine for resectable pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4105-4105.	1.6	4
161	Outcome of second-line treatment (2L Tx) following nab-paclitaxel (nab-P) + gemcitabine (G) or G alone for metastatic pancreatic cancer (MPC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 333-333.	1.6	2
162	Evaluation of circulating VEGF based biomarkers in INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC) œ A study by the Australasian Gastrointestinal Trials Group (AGITG).. <i>Journal of Clinical Oncology</i> , 2016, 34, 64-64.	1.6	3

#	ARTICLE	IF	CITATIONS
163	APACT: Phase III randomized trial of adjuvant treatment with nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with resected pancreatic cancer (PC).. Journal of Clinical Oncology, 2016, 34, TPS473-TPS473.	1.6	8
164	Overcoming resistance of targeted EGFR monotherapy by inhibition of STAT3 escape pathway in soft tissue sarcoma. Oncotarget, 2016, 7, 21496-21509.	1.8	20
165	Targeting the PI3K/PTEN/AKT/mTOR Pathway in Treatment of Sarcoma Cell Lines. Anticancer Research, 2016, 36, 5765-5772.	1.1	23
166	Systemic therapy in elderly patients with advanced biliary tract cancer: Sub-analysis of ABC-02 and 10 other prospective studies.. Journal of Clinical Oncology, 2016, 34, 382-382.	1.6	0
167	Meta-analysis of radical resection rates and margin assessment in pancreatic cancer. British Journal of Surgery, 2015, 102, 1459-1472.	0.3	158
168	Oncology service initiatives and research in regional Australia. Australian Journal of Rural Health, 2015, 23, 40-48.	1.5	17
169	Describing Patterns of Care in Pancreatic Cancer. Pancreas, 2015, 44, 1259-1265.	1.1	30
170	Exploiting base excision repair to improve therapeutic approaches for pancreatic cancer. Frontiers in Nutrition, 2015, 2, 10.	3.7	22
171	Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. Journal of Clinical Oncology, 2015, 33, 4276-4283.	1.6	148
172	Response. Journal of the National Cancer Institute, 2015, 107, djv206.	6.3	0
173	nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial. Journal of the National Cancer Institute, 2015, 107, dju413-dju413.	6.3	487
174	Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer. Oncologist, 2015, 20, 143-150.	3.7	123
175	The Potential of panHER Inhibition in Cancer. Frontiers in Oncology, 2015, 5, 2.	2.8	33
176	Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial. Haematologica, 2015, 100, 955-963.	3.5	75
177	Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. European Journal of Cancer, 2015, 51, 852-860.	2.8	23
178	Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2015, 75, 993-1004.	2.3	12
179	EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma. Annals of Oncology, 2015, 26, 1118-1123.	1.2	11
180	Pancreatic cancer: The microenvironment needs attention too!. Pancreatology, 2015, 15, S32-S38.	1.1	69

#	ARTICLE	IF	CITATIONS
181	Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. <i>British Journal of Cancer</i> , 2015, 113, 1571-1580.	6.4	88
182	Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations. <i>Genetics in Medicine</i> , 2015, 17, 391-395.	2.4	41
183	Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. <i>BMC Cancer</i> , 2015, 15, 564.	2.6	182
184	Migrant Health in Cancer: Outcome Disparities and the Determinant Role of Migrant-Specific Variables. <i>Oncologist</i> , 2015, 20, 523-531.	3.7	46
185	INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG)â€™Final overall and subgroup results.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4003-4003.	1.6	11
186	A multicenter, phase II trial of preoperative gemcitabine and nab-paclitaxel for resectable pancreas cancer: The AGITG GAP study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4115-4115.	1.6	5
187	TOPS: A randomised controlled trial of a multidisciplinary intervention for post-cancer fatigue.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9571-9571.	1.6	4
188	Antiangiogenic agents (AAs) in metastatic oesophago-gastric cancer (mOGC): A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15111-e15111.	1.6	1
189	Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1): A randomized, multidisciplinary, multinational phase III trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS4140-TPS4140.	1.6	1
190	<i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (Gem) vs Gem alone as adjuvant treatment for resected pancreatic cancer (PC) in a phase III trial (APACT).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS4153-TPS4153.	1.6	1
191	Prognosis model for overall survival in locally advanced unresectable pancreatic carcinoma: An ancillary study of the LAP 07 trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 235-235.	1.6	1
192	Tumor reduction in pancreatic versus metastatic sites in a randomized phase III study (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone.. <i>Journal of Clinical Oncology</i> , 2015, 33, 382-382.	1.6	1
193	A multicenter, phase II trial of preoperative gemcitabine and nab-paclitaxel for resectable pancreas cancer: The AGITG GAP study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 387-387.	1.6	4
194	INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)â€™A study by the Australasian Gastrointestinal Trials Group (AGITG), first results.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9-9.	1.6	7
195	Î²III-Tubulin: A novel mediator of chemoresistance and metastases in pancreatic cancer. <i>Oncotarget</i> , 2015, 6, 2235-2249.	1.8	57
196	Reduction in primary pancreatic and metastatic tumor burden in the phase III MPACT trial of <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (Gem) versus Gem alone.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15299-e15299.	1.6	0
197	Albumin-Bound Paclitaxel plus Gemcitabine in Pancreatic Cancer. <i>New England Journal of Medicine</i> , 2014, 370, 478-480.	27.0	52
198	Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer. <i>Frontiers in Physiology</i> , 2014, 5, 2.	2.8	57

#	ARTICLE	IF	CITATIONS
199	The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: antiangiogenic implications in pancreatic cancer. <i>Carcinogenesis</i> , 2014, 35, 1891-1900.	2.8	72
200	Role of pancreatic stellate cells in chemoresistance in pancreatic cancer. <i>Frontiers in Physiology</i> , 2014, 5, 141.	2.8	122
201	Human papillomavirus (HPV) genotypes in an Australian sample of anal cancers. <i>International Journal of Cancer</i> , 2014, 135, 996-1001.	5.1	42
202	Immigrants' perceptions of the quality of their cancer care: an Australian comparative study, identifying potentially modifiable factors. <i>Annals of Oncology</i> , 2014, 25, 1643-1649.	1.2	81
203	Characterization of Fatigue States in Medicine and Psychiatry by Structured Interview. <i>Psychosomatic Medicine</i> , 2014, 76, 379-388.	2.0	20
204	Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt347.	6.3	231
205	Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 504-512.	1.6	351
206	Assessing the invariance of a culturally competent multi-lingual unmet needs survey for immigrant and Australian-born cancer patients: a Rasch analysis. <i>Quality of Life Research</i> , 2014, 23, 2819-2830.	3.1	7
207	Correlation of <i>KIT</i> and <i>PDGFRA</i> mutational status with clinical benefit in patients (pts) with gastrointestinal stromal tumor (GIST) treated with sunitinib (SU) in a worldwide treatment-use (TU) trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10549-10549.	1.6	1
208	Impact of chemoradiotherapy (CRT) on local control and time without treatment in patients with locally advanced pancreatic cancer (LAPC) included in the international phase III LAP 07 study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4001-4001.	1.6	25
209	Genetic associations of fatigue and other symptom domains after breast cancer treatment: Results from a prospective cohort study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9537-9537.	1.6	1
210	APACT: A phase 3 randomized, open-label, multicenter trial evaluating the use of adjuvant nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with surgically resected ductal pancreatic adenocarcinoma (PDA).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS4162-TPS4162.	1.6	5
211	Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas.. <i>Journal of Clinical Oncology</i> , 2014, 32, 178-178.	1.6	17
212	Human equilibrative nucleoside transporter 1 (hENT1) in gemcitabine and FOLFOX (oxaliplatin,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 22 phase II PAN1 study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 228-228.	1.6	2
213	Analysis of metabolic response (MR) by positron emission tomography (PET) compared with tumor response by computed tomography (CT) from MPACT, a phase III trial comparing nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone for patients (pts) with metastatic adenocarcinoma of the pancreas.. <i>Journal of Clinical Oncology</i> , 2014, 32, 254-254.	1.6	4
214	Circulating biomarkers and outcomes in a single-arm phase II trial of first-line sunitinib alternating with everolimus for advanced renal cell carcinoma (aRCC): EVERSUN ANZUP trial 0901.. <i>Journal of Clinical Oncology</i> , 2014, 32, 428-428.	1.6	1
215	EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (aRCC) (ANZUP trial 0901).. <i>Journal of Clinical Oncology</i> , 2014, 32, 438-438.	1.6	0
216	Analyses of updated overall survival (OS) and prognostic effect of neutrophil-to-lymphocyte ratio (NLR) and CA 19-9 from the phase III MPACT study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem for patients (pts) with metastatic pancreatic cancer (PC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4027-4027.	1.6	2

#	ARTICLE	IF	CITATIONS
217	Prognosis model for overall survival in locally advanced pancreatic cancer (LAPC): An ancillary study of the LAP 07 trial.. Journal of Clinical Oncology, 2014, 32, 4024-4024.	1.6	1
218	Impact of STAT3 inhibition on survival of osteosarcoma cell lines. Anticancer Research, 2014, 34, 6537-45.	1.1	15
219	Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. New England Journal of Medicine, 2013, 369, 1691-1703.	27.0	5,097
220	Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Genome Medicine, 2013, 5, 78.	8.2	97
221	Chemotherapy-induced peripheral neurotoxicity: A critical analysis. Ca-A Cancer Journal for Clinicians, 2013, 63, 419-437.	329.8	547
222	Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates.. Journal of Clinical Oncology, 2013, 31, 4005-4005.	1.6	18
223	CA19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC).. Journal of Clinical Oncology, 2013, 31, 4058-4058.	1.6	5
224	Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC).. Journal of Clinical Oncology, 2013, 31, 4059-4059.	1.6	6
225	The unmet needs of cancer survivors and their preferences for discussing them with oncologists and general practitioners (GPs).. Journal of Clinical Oncology, 2013, 31, 9602-9602.	1.6	1
226	Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.. Journal of Clinical Oncology, 2013, 31, LBA4003-LBA4003.	1.6	31
227	INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced esophagogastric cancer (AOGC)â€”A study by the Australasian Gastrointestinal Trials Group (AGITG).. Journal of Clinical Oncology, 2013, 31, TPS4157-TPS4157.	1.6	3
228	Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.. Journal of Clinical Oncology, 2013, 31, LBA4003-LBA4003.	1.6	61
229	Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT).. Journal of Clinical Oncology, 2013, 31, LBA148-LBA148.	1.6	57
230	Should culture affect practice? Prognostic discussions with immigrants.. Journal of Clinical Oncology, 2013, 31, 6556-6556.	1.6	0
231	Significance of baseline quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3.. Journal of Clinical Oncology, 2013, 31, 4053-4053.	1.6	1
232	Targeted therapy in soft tissue sarcoma-a novel direction in therapeutics. Chinese Clinical Oncology, 2013, 2, 22.	1.2	2
233	A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	1.2	44
234	Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure. Clinical Cancer Research, 2012, 18, 3170-3179.	7.0	116

#	ARTICLE	IF	CITATIONS
235	Post-cancer fatigue is not associated with immune activation or altered cytokine production. <i>Annals of Oncology</i> , 2012, 23, 2890-2895.	1.2	18
236	Reply to A. Giacalone et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 4175-4176.	1.6	0
237	The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine+oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer. <i>British Journal of Cancer</i> , 2012, 106, 61-69.	6.4	14
238	Cancer-Related Fatigue in Women With Breast Cancer: Outcomes of a 5-Year Prospective Cohort Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 1805-1812.	1.6	114
239	STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers. <i>International Journal of Oncology</i> , 2012, 41, 1181-1191.	3.3	172
240	Cancer survivorship outcomes in immigrants.. <i>Journal of Clinical Oncology</i> , 2012, 30, 6111-6111.	1.6	3
241	Predictors of resilience in women treated for breast cancer: A prospective study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9044-9044.	1.6	3
242	Disparities in quality-of-life outcomes in immigrant cancer patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, e16507-e16507.	1.6	1
243	ATTACHE: A phase III, multicenter, randomized comparison of chemotherapy given prior to and post surgical resection versus chemotherapy given post surgical resection for hepatic metastases from colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS3643-TPS3643.	1.6	0
244	Usefulness of medical oncologists'™ estimates of survival time in people with advanced cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9087-9087.	1.6	0
245	PAN1: A randomized phase II study evaluating potential predictive biomarkers in the treatment of metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS4137-TPS4137.	1.6	0
246	Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 519-525.	2.3	9
247	Long-Term Neuropathy After Oxaliplatin Treatment: Challenging the Dictum of Reversibility. <i>Oncologist</i> , 2011, 16, 708-716.	3.7	171
248	If I Am in the Mood, I Enjoy It: An Exploration of Cancer-Related Fatigue and Sexual Functioning in Women with Breast Cancer. <i>Oncologist</i> , 2011, 16, 1333-1344.	3.7	84
249	A Serious Complication of Selected Internal Radiation Therapy: Case Report and Literature Review. <i>Oncologist</i> , 2010, 15, 830-835.	3.7	54
250	Role of Pancreatic Stellate Cells in Pancreatic Cancer Metastasis. <i>American Journal of Pathology</i> , 2010, 177, 2585-2596.	3.8	304
251	Treatment of Fluorouracil-Refractory Patients With Liver Metastases From Colorectal Cancer by Using Yttrium-90 Resin Microspheres Plus Concomitant Systemic Irinotecan Chemotherapy. <i>Journal of Clinical Oncology</i> , 2009, 27, 4089-4095.	1.6	142
252	Acute Abnormalities of Sensory Nerve Function Associated With Oxaliplatin-Induced Neurotoxicity. <i>Journal of Clinical Oncology</i> , 2009, 27, 1243-1249.	1.6	153

#	ARTICLE	IF	CITATIONS
253	The successful management of two pregnancies with wild type metastatic gastrointestinal stromal tumors. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2009, 5, 187-192.	1.1	1
254	Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2009, 101, 998-1004.	6.4	84
255	Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. <i>Brain</i> , 2009, 132, 2712-2723.	7.6	198
256	ESPAC-3(v2): A multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, LBA4505-LBA4505.	1.6	13
257	GOFURTO trial (GFG): An AGITG multicenter phase II study of fixed dose rate gemcitabine-oxaliplatin (Gem-Ox) integrated with concomitant 5FU and 3-D conformal radiotherapy (5FU-3DRT) for the treatment of locally advanced pancreatic cancer (LAPC). <i>Journal of Clinical Oncology</i> , 2009, 27, 4616-4616.	1.6	2
258	ESPAC-3(v2): A multicenter, international, open-label, randomized controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, LBA4505-LBA4505.	1.6	13
259	Response of Carney's triad-related metastatic gastrointestinal stromal tumor to sunitinib. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2008, 4, 170-174.	1.1	2
260	Pancreatic Stellate Cells: Partners in Crime with Pancreatic Cancer Cells. <i>Cancer Research</i> , 2008, 68, 2085-2093.	0.9	417
261	Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer. <i>British Journal of Cancer</i> , 2007, 97, 464-471.	6.4	35
262	Modification of Leucovorin Dose Within a Simplified FOLFOX Regimen Improves Tolerability Without Compromising Efficacy. <i>Clinical Colorectal Cancer</i> , 2007, 6, 578-582.	2.3	3
263	ABC; An AGITG trial of fixed dose rate (FDR) gemcitabine (gem) and cisplatin for patients (pts) with advanced biliary tract cancer (ABC). <i>Journal of Clinical Oncology</i> , 2007, 25, 15015-15015.	1.6	0
264	Prognostic Factors Predictive of Response and Survival to a Modified FOLFOX Regimen: Importance of an Increased Neutrophil Count. <i>Clinical Colorectal Cancer</i> , 2006, 6, 297-304.	2.3	29
265	Hypersensitivity reactions to oxaliplatin: Can patients be rechallenged?. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2006, 2, 175-179.	1.1	2
266	Phase II study of vinflunine in patients with metastatic renal cell carcinoma. <i>Investigational New Drugs</i> , 2006, 24, 429-434.	2.6	18
267	Fatigue states after cancer treatment occur both in association with, and independent of, mood disorder: a longitudinal study. <i>BMC Cancer</i> , 2006, 6, 240.	2.6	79
268	Randomised phase II study evaluating weekly docetaxel in combination with cisplatin and 5FU or capecitabine in metastatic oesophago-gastric cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 4067-4067.	1.6	1
269	Oxaliplatin-induced neurotoxicity and the development of neuropathy. <i>Muscle and Nerve</i> , 2005, 32, 51-60.	2.2	194
270	Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients. <i>British Journal of Cancer</i> , 2005, 92, 832-837.	6.4	21

#	ARTICLE	IF	CITATIONS
271	Initial and Late Resistance to Imatinib in Advanced Gastrointestinal Stromal Tumors Are Predicted by Different Prognostic Factors: A European Organisation for Research and Treatment of Cancerâ€“Italian Sarcoma Groupâ€“Australasian Gastrointestinal Trials Group Study. Journal of Clinical Oncology, 2005, 23, 5795-5804.	1.6	266
272	Gastrointestinal Stromal Tumours: Correlation of ¹⁸ F-FDG Gamma Camera-Based Coincidence Positron Emission Tomography with CT for the Assessment of Treatment Response â€“ An AGITG Study. Oncology, 2005, 69, 326-332.	1.9	31
273	Modern management of pancreatic carcinoma. Internal Medicine Journal, 2004, 34, 475-481.	0.8	38
274	Fatigue and psychological distress â€“ exploring the relationship in women treated for breast cancer. European Journal of Cancer, 2004, 40, 1689-1695.	2.8	54
275	Desmoplastic Reaction in Pancreatic Cancer. Pancreas, 2004, 29, 179-187.	1.1	530
276	Combined modality therapy for pancreatic carcinoma - An Australian Pancreatic Cancer Group study of the addition of gemcitabine to concurrent infusional 5-fluorouracil and 3D conformal radiotherapy. Journal of Clinical Oncology, 2004, 22, 4100-4100.	1.6	1
277	Communicating in a multicultural society II: Greek community attitudes towards cancer in Australia. Internal Medicine Journal, 2002, 32, 289-296.	0.8	58
278	Administration of Imiquimod, an Interferon Inducer, in Asymptomatic Human Immunodeficiency Virusâ€“Infected Persons to Determine Safety and Biologic Response Modification. Journal of Infectious Diseases, 1998, 178, 858-861.	4.0	66
279	What is hemoglobin A1c? An analysis of glycated hemoglobins by electrospray ionization mass spectrometry. Clinical Chemistry, 1998, 44, 1951-1958.	3.2	169
280	Australian Leukaemia Study Group Myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma. British Journal of Haematology, 1997, 97, 38-45.	2.5	28